OncLive and Targeted Oncology: Drug yields long-lasting benefits to treat PEComa tumors
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.
At the 2024 SGO Annual Meeting on Women's Cancer, Herzog presented results from a subgroup analysis of the phase 2 AMPECT trial. Nab-sirolimus is the first and only FDA-approved treatment for advanced PEComa.
"The median time to response was extremely fast, about 1.4 months, and the duration of response was a little over 36 months," Herzog, MD, a University of Cincinnati Cancer Center member, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center, told Targeted Oncology. "It is important to remember these responses occur often rapidly, and they are quite durable."
Watch the Targeted Oncology video.
Featured photo at top of Thomas Herzog. Photo provided.
Related Stories
UC part of $18 million initiative to expand behavioral health workforce in Ohio
September 23, 2026
The University of Cincinnati is participating in a new $18 million statewide scholarship program, as Cleveland.com recently reported, to address critical shortages of mental health and substance use treatment providers across Ohio.
Unlike many parents, children are fearless around AI
September 23, 2026
Researchers at the University of Cincinnati found that children ages 5-10 are enthusiastic about playing with new AI toys but also tend to believe what the AI tells them. Their embrace of AI contrasts with concerns expressed by some of their parents.
Is Cincinnati building new homes fast enough?
September 22, 2026
Gary Painter, professor and academic director of the Real Estate Center at UC's Lindner College of Business, offers comments on affordability issues in Cincinnati.